Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

Rhea-AI Summary

Insmed, a biopharmaceutical company focused on rare diseases, plans to release its Q1 2022 financial results on May 5, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call via phone or through a live webcast on the company's website. Insmed aims to transform lives with innovative therapies and is progressing in various serious unmet medical needs.

Positive

• Insmed will release Q1 2022 financial results on May 5, 2022.
• Management will host a conference call to discuss financial results and business updates.

Negative

• None.

BRIDGEWATER, N.J., April 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, May 5, 2022 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S. toll free), (646) 904-5544 (U.S. local), or +1-929-526-1599 (international) and referencing access code 388457. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion through June 4, 2022, by dialing (866) 813-9403 (U.S. toll free), (929) 458-6194 (U.S. local), or +44-204-525-0658 (international) and referencing access code 252664. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-first-quarter-2022-financial-results-conference-call-on-thursday-may-5-2022-301527707.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its Q1 2022 financial results?

Insmed will release its Q1 2022 financial results on May 5, 2022.

What time is the Insmed conference call for Q1 2022 results?

The Insmed conference call will take place at 8:30 a.m. ET on May 5, 2022.

How can I access the Insmed financial results conference call?

You can access the conference call by dialing the provided numbers or through a live webcast on Insmed's website.

What is the main focus of Insmed as a biopharmaceutical company?

Insmed focuses on transforming the lives of patients with serious and rare diseases.